Abstract
ObjectiveMyasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have